Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04085887 · ClinicalTrials.gov registry record · Phase 1
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
A Phase 1 study of Brain Tumor, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04085887 is a Phase 1 study of Brain Tumor that is actively recruiting participants, run by Stanford University. The registered enrollment target is 12 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04085887, a Phase 1 study of Brain Tumor, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
Conditions Studied
Interventions
- DRUG Panitumumab-IRDye800
- DEVICE Pinpoint-IR9000 endoscopic/handheld device
- DEVICE Explorer Air camera
- DEVICE PDE-NEO-II
Study Locations (1)
California
- Stanford Cancer Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04085887
The ClinicalTrials.gov registry entry for NCT04085887 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (96% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 4 interventions - of which Panitumumab-IRDye800 is the first listed.
NCT04085887 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04085887 about?
NCT04085887 is a clinical study titled "Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures". The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
What is the current status of trial NCT04085887?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-04. Estimated completion is 2028-12.
What conditions does trial NCT04085887 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT04085887?
The interventions under investigation include: Panitumumab-IRDye800 (DRUG), Pinpoint-IR9000 endoscopic/handheld device (DEVICE), Explorer Air camera (DEVICE), PDE-NEO-II (DEVICE).
Who is sponsoring clinical trial NCT04085887?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04085887 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.